Hotsia.Com : เที่ยวสะใจ

How does nonsteroidal MRA (e.g., finerenone) modify CV-renal outcomes, what trials show, and how does this compare with spironolactone in hyperkalemia risk?

A nonsteroidal mineralocorticoid receptor antagonist (MRA) like finerenone modifies cardio-renal outcomes by selectively blocking the mineralocorticoid receptor (MR) to reduce inflammation and fibrosis in the heart and kidneys. Unlike older, steroidal MRAs, finerenone’s mechanism is not just about fluid and electrolyte balance; it has a direct anti-inflammatory and anti-fibrotic effect. Overactivation of the MR, driven by aldosterone and other factors, leads to chronic inflammation and tissue scarring in cardiorenal disease. By potently and selectively binding to the MR, finerenone interrupts this pathological process, preventing progressive organ damage and thereby reducing the risk of cardiovascular events and kidney disease progression. This unique action provides organ protection that is complementary to therapies that target the renin-angiotensin system (e.g., ACEi/ARBs), making it a valuable addition to standard care.

📉 Clinical Trial Outcomes

The impact of finerenone on cardiorenal outcomes is supported by extensive evidence from large-scale, landmark randomized controlled trials. The FIDELIO-DKD and FIGARO-DKD trials, which enrolled over 13,000 patients with chronic kidney disease (CKD) and type 2 diabetes, demonstrated finerenone’s ability to significantly reduce both cardiovascular and kidney-related adverse events. In FIDELIO-DKD, finerenone reduced the risk of a composite kidney outcome (kidney failure, sustained eGFR decline, or renal death) by 18%. It also reduced the risk of a composite cardiovascular outcome (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure hospitalization) by 14%. The FIGARO-DKD trial, which included patients with a less advanced stage of CKD, also showed a significant reduction in cardiovascular outcomes, primarily driven by a reduction in heart failure hospitalization. These findings were consistent across a wide range of patients and were largely independent of blood pressure changes. This robust body of evidence established finerenone as the first nonsteroidal MRA to show both cardiovascular and renal benefits in this high-risk patient population, leading to its approval and inclusion in clinical guidelines.

⚖️ Hyperkalemia Risk: Finerenone vs. Spironolactone

The risk of hyperkalemia is a major distinguishing factor between finerenone and the older, steroidal MRA spironolactone. While all MRAs can cause hyperkalemia by retaining potassium, finerenone has a much lower risk. This difference is primarily due to its pharmacological properties and distribution profile. Spironolactone has an equal affinity for MRs in both the kidney and the heart. Finerenone, on the other hand, is a more selective and nonsteroidal agent with a balanced distribution between the heart and kidney, and it exhibits a lower propensity to cause hyperkalemia. Clinical trial data confirms this. Post-hoc analyses and direct comparisons have shown that finerenone is associated with a significantly lower incidence of hyperkalemia compared to spironolactone. For example, some studies found that the incidence of mild-to-moderate hyperkalemia was significantly lower with finerenone. Furthermore, the rate of treatment discontinuation due to hyperkalemia is also substantially lower with finerenone, which is crucial for long-term adherence and a better safety profile. This reduced hyperkalemia risk makes finerenone a more attractive and safer option for patients with CKD, who are already at a high baseline risk for this dangerous side effect, allowing more individuals to receive the benefits of MRA therapy without the same level of concern.

 

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. I share my experiences on www.hotsia.com